More on ASGLY
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $9.14 |
|
|||
| Open | $9.43 | ||||
| 52 Wk High | $6.92 | ||||
| 52 Wk Low | $4.65 | ||||
| Day High | $9.51 | ||||
| Day Low | $9.43 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,947 | ||||
- AGC Inc (5201:JP) (ASGLY) PT Raised to JPY7,500 at JPMorgan
- AGC Completes Third-Party Verification Under UL 2809 for Fluorine Raw Materials Used in AFLAS™ FFKM
- AGC Biologics to Manufacture Teikoku Seiyaku's rhMMP-7 Drug Substance
- Nomura/Instinet Upgrades AGC Inc (5201:JP) (ASGLY) to Buy
- AGC Biologics Joins Orphan Therapeutics Accelerator’s Clinical Development Network as a Manufacturing Partner to Advance Cell and Gene Therapies for Ultra-Rare Diseases
- AGC Biologics Wins 2026 Fierce Outsourcing Award for Leadership in Regulatory and Quality Compliance
- Citi Downgrades AGC Inc (5201:JP) (ASGLY) to Neutral
- AGC Inc (5201:JP) (ASGLY) PT Raised to JPY6,320 at Nomura/Instinet
- AGC Biologics Seattle Site Now Certified to Manufacture Biologics for Largest Pharmaceutical Market in South America
- AGC Biologics Celebrates U.S. and EU Approval of Fondazione Telethon’s Waskyra™ Treatment for Wiskott-Aldrich Syndrome
Entities mentioned with ASGLY
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Deutsche Bank | View Related Stories »
- Dividend | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
